Abstract
Emerging evidence indicates that cardiomyocytes can be regenerated from embryonic stem cells, adult mesenchymal stem cells, and cardiac side population cells (cardiac stem cells). When these cells were injected into diseased hearts, indices of cardiac function improved. There are ethical difficulties involved in the use of embryonic stem cells. The ratio of differentiation into cardiomyocytes is still relatively low at present. Transplantation of regenerated cardiomyocytes or stem cells, however, will become a future therapy for severe heart failure.
| Original language | English |
|---|---|
| Pages (from-to) | 454-458 |
| Number of pages | 5 |
| Journal | Nippon Geka Gakkai zasshi |
| Volume | 105 |
| Issue number | 8 |
| Publication status | Published - 2004 |
Fingerprint
Cite this
Regenerative medicine in cardiology. / Manabe, Tomohiro; Fukuda, Keiichi.
In: Nippon Geka Gakkai zasshi, Vol. 105, No. 8, 2004, p. 454-458.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Regenerative medicine in cardiology
AU - Manabe, Tomohiro
AU - Fukuda, Keiichi
PY - 2004
Y1 - 2004
N2 - Emerging evidence indicates that cardiomyocytes can be regenerated from embryonic stem cells, adult mesenchymal stem cells, and cardiac side population cells (cardiac stem cells). When these cells were injected into diseased hearts, indices of cardiac function improved. There are ethical difficulties involved in the use of embryonic stem cells. The ratio of differentiation into cardiomyocytes is still relatively low at present. Transplantation of regenerated cardiomyocytes or stem cells, however, will become a future therapy for severe heart failure.
AB - Emerging evidence indicates that cardiomyocytes can be regenerated from embryonic stem cells, adult mesenchymal stem cells, and cardiac side population cells (cardiac stem cells). When these cells were injected into diseased hearts, indices of cardiac function improved. There are ethical difficulties involved in the use of embryonic stem cells. The ratio of differentiation into cardiomyocytes is still relatively low at present. Transplantation of regenerated cardiomyocytes or stem cells, however, will become a future therapy for severe heart failure.
UR - http://www.scopus.com/inward/record.url?scp=7044269322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7044269322&partnerID=8YFLogxK
M3 - Article
C2 - 15373222
AN - SCOPUS:7044269322
VL - 105
SP - 454
EP - 458
JO - Nihon Geka Gakkai zasshi
JF - Nihon Geka Gakkai zasshi
SN - 0301-4894
IS - 8
ER -